
Oral TOFA Triggers Fat Burn, Preserves Muscle, and Boosts Obesity Drugs in Mice
A preclinical study in obese mice shows the oral compound TOFA reduces body weight by about 18% without changing food intake or causing muscle loss, by both limiting fat production and increasing cellular energy expenditure (about 18%). TOFA also improves fatty liver disease and blood lipid markers. When combined with obesity drugs like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound), the cotreatments outperform single drugs and maintain weight loss longer after treatment ends, suggesting a complementary mechanism that could enhance current therapies. Human safety and dosing remain unknown, and the work is limited to animal models.













